Research Article
Integrative Molecular Analyses of an Individual Transcription Factor-Based Genomic Model for Lung Cancer Prognosis
Table 2
GO enrichment results enriched by downstream targets of three TFs.
| Description | Gene ratio | BgRatio | value | FDR | value | Count |
| Rhythmic process | 20/277 | 294/18862 | 1.48-08 | 3.08-05 | 2.45-05 | 20 | Circadian rhythm | 17/277 | 212/18862 | 1.67-08 | 3.08-05 | 2.45-05 | 17 | Circadian regulation of gene expression | 10/277 | 67/18862 | 4.71-08 | 5.21-05 | 4.14-05 | 10 | Anterior/posterior pattern specification | 16/277 | 203/18862 | 5.64-08 | 5.21-05 | 4.14-05 | 16 | Regionalization | 20/277 | 326/18862 | 8.22-08 | 6.07-05 | 4.83-05 | 20 | Positive regulation of protein localization to cell periphery | 9/277 | 67/18862 | 5.67-07 | 0.000349 | 0.000277 | 9 | Regulation of circadian rhythm | 11/277 | 118/18862 | 1.34-06 | 0.000665 | 0.000529 | 11 | Pattern specification process | 21/277 | 426/18862 | 1.44-06 | 0.000665 | 0.000529 | 21 | Entrainment of circadian clock by photoperiod | 6/277 | 29/18862 | 3.40-06 | 0.001394 | 0.001108 | 6 | Muscle organ development | 17/277 | 317/18862 | 4.90-06 | 0.001716 | 0.001365 | 17 | Early endosome membrane | 11/283 | 162/19520 | 2.53-05 | 0.008847 | 0.008168 | 11 | Early endosome | 15/283 | 378/19520 | 0.00044 | 0.076941 | 0.07104 | 15 | Nuclear speck | 14/283 | 411/19520 | 0.002834 | 0.255165 | 0.235596 | 14 | Presynaptic active zone | 5/283 | 70/19520 | 0.003472 | 0.255165 | 0.235596 | 5 | Recycling endosome | 8/283 | 190/19520 | 0.006657 | 0.255165 | 0.235596 | 8 | Mitotic spindle | 7/283 | 157/19520 | 0.008067 | 0.255165 | 0.235596 | 7 | Recycling endosome membrane | 5/283 | 87/19520 | 0.008695 | 0.255165 | 0.235596 | 5 | Catalytic step 2 spliceosome | 5/283 | 87/19520 | 0.008695 | 0.255165 | 0.235596 | 5 | Cell-substrate junction | 13/283 | 423/19520 | 0.009108 | 0.255165 | 0.235596 | 13 | Ribonucleoprotein granule | 9/283 | 244/19520 | 0.009482 | 0.255165 | 0.235596 | 9 | DNA-binding transcription activator activity, RNA polymerase II-specific | 19/285 | 443/18337 | 6.93-05 | 0.008115 | 0.007448 | 19 | DNA-binding transcription activator activity | 19/285 | 447/18337 | 7.80-05 | 0.008115 | 0.007448 | 19 | E-box binding | 6/285 | 47/18337 | 8.41-05 | 0.008115 | 0.007448 | 6 | Cytokine receptor binding | 14/285 | 270/18337 | 8.94-05 | 0.008115 | 0.007448 | 14 | Transcription corepressor binding | 5/285 | 30/18337 | 9.07-05 | 0.008115 | 0.007448 | 5 | DNA-binding transcription repressor activity, RNA polymerase II-specific | 15/285 | 307/18337 | 9.81-05 | 0.008115 | 0.007448 | 15 | DNA-binding transcription repressor activity | 15/285 | 309/18337 | 0.000105 | 0.008115 | 0.007448 | 15 | Protein-cysteine S-palmitoyltransferase activity | 4/285 | 28/18337 | 0.000872 | 0.052206 | 0.047919 | 4 | Protein-cysteine S-acyltransferase activity | 4/285 | 28/18337 | 0.000872 | 0.052206 | 0.047919 | 4 | Tumor necrosis factor receptor binding | 4/285 | 31/18337 | 0.001292 | 0.069613 | 0.063896 | 4 |
|
|